

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED**

北京同仁堂國藥有限公司

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3613)**

**VOLUNTARY ANNOUNCEMENT  
INCREASE IN SHAREHOLDING BY DIRECTORS**

This announcement is made by Beijing Tong Ren Tang Chinese Medicine Company Limited (the “**Company**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company was informed by Ms. Ding Yong Ling (“**Ms. Ding**”), the chairman of the Board and the executive director of the Company, Mr. Zhang Huan Ping (“**Mr. Zhang**”), the chief executive officer and the executive director of the Company and Ms. Lin Man (“**Ms. Lin**”), the chief operating officer and the executive director of the Company, that during the period of 8 September and 11 September 2020, Ms. Ding acquired 42,000 shares of the Company (the “**Shares**”) on the market for an aggregate consideration of approximately HK\$355,000 (representing an average price of approximately HK\$8.45 per Share), Mr. Zhang acquired 100,000 Shares on the market for an aggregate consideration of approximately HK\$834,000 (representing an average price of approximately HK\$8.34 per Share), and Ms. Lin acquired 20,000 Shares on the market for an aggregate consideration of approximately HK\$170,800 (representing an average price of approximately HK\$8.54 per Share) (collectively the “**Share Purchases**”).

As at the date of this announcement, after the Share Purchases, Ms. Ding holds a total of 410,000 Shares, representing approximately 0.049% of the total number of Shares in issue; Mr. Zhang holds a total of 100,000 Shares, representing approximately 0.012% of the total number of Shares in issue; Ms. Lin holds a total of 290,000 Shares, representing approximately 0.035% of the total number of Shares in issue. The Share Purchases fully demonstrate Ms. Ding, Mr. Zhang and Ms. Lin’s confidence in the overall development prospects and growth potential of the Company.

Based on the information available to the Company and to the best knowledge of the Board, the Company has maintained sufficient public float of the issued Shares immediately following the Share Purchases and as at the date of this announcement.

By order of the Board  
**Beijing Tong Ren Tang**  
**Chinese Medicine Company Limited**  
**Ding Yong Ling**  
*Chairman*

Hong Kong, 14 September 2020

*As at the date of this announcement, the Board comprises the executive directors, namely Ms. Ding Yong Ling (Chairman), Mr. Zhang Huan Ping and Ms. Lin Man; the non-executive director, namely Mr. Chen Fei; and the independent non-executive directors, namely Mr. Tsang Yok Sing, Jasper, Mr. Zhao Zhong Zhen and Mr. Chan Ngai Chi.*